Sorrento Medical Company Sorrento Therapeutics, Inc. (NASDAQ:SRNE) was founded in 2006 and is headquartered in San Diego, California, with 310 full-time employees. It is a clinical-stage biopharmaceutical company mainly engaged in oncology treatment and global chronic cancer pain Discovery and development of treatments.
Sorrento Therapeutics (SRNE):
Sorrento Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to the development of therapies for the treatment of cancer, autoimmune diseases, inflammatory diseases and neurodegenerative diseases. The company operates through two parts: Sorrento Therapeutics and Scilex.
Sorrento Therapeutics provides cancer therapies by using its proprietary G-MAB antibody library and targeted delivery methods, including chimeric antigen receptor T cell therapy (CAR-T), dimeric antigen receptor T cell therapy, and antibodies Drug conjugates and bispecific antibody methods.
Sorrento Medical also offers Sofusa, a drug delivery technology that delivers biological agents directly to the lymphatic system.
In addition, Sorrento Therapeutics is developing clinical programs that include anti-CD38 CAR-T therapies to treat multiple myeloma, amyloidosis, and graft-versus-host disease.
In addition, Sorrento Therapeutics has also developed resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, which can be used for the treatment of advanced cancer and osteoarthritis knee pain; and ZTlido, a lidocaine delivery system for Treatment of neuralgia after herpes zoster.
In addition, Sorrento Therapeutics is also engaged in the development of SEMDEXA (an injectable viscous gel formulation) and is currently in a phase III clinical trial for the treatment of sciatica (a condition of low back pain); and SP-103, one A non-hydraulic lidocaine topical medication system under study is under clinical development for chronic low back pain.
In addition, Sorrento Therapeutics, Inc. and SmartPharm Therapeutics Inc. cooperated to develop genetically encoded antibody vaccines to prevent COVID-19 (new crown virus pneumonia); and the University of Texas at Galveston (The University of Texas Medical Branch at Galveston) has signed a research and testing agreement to conduct preclinical testing of Sorrento Therapeutics’ COVID-19 (new crown virus pneumonia) therapeutic drug candidates; Sorrento Therapeutics is also conducting research on COVID-19 with Celularity, Inc., Cooperate to carry out Phase I/II clinical studies, including up to 86 COVID-19 patients.
Sorrento Medical has also signed a license agreement with Mabtech Limited to develop and commercialize a variety of pre-designated biosimilars and biological antibodies based on Erbitux, Remicade, Xolair and Simulect.
The latest news from Sorrento Therapeutics (SRNE):
- In July 2016, WuXi AppTec’s partner Sorrento Therapeutics recently announced that it has reached a licensing and cooperation agreement with Servier , one of France’s largest privately -traded pharmaceutical companies , to jointly develop, produce and commercialize Sorrento’s research team. Anti-PD-1 monoclonal antibody STI-A1110, as a potential cancer immunotherapy drug.
- At the end of January 2020, Sorrento Therapeutics rejected an acquisition proposal. Earlier, Sorrento received the latest acquisition proposal from a private equity fund.
- On May 15, 2020 , Sorrento Therapeutics provided an optimistic assessment of the results of its COVID-19 virus (new crown pneumonia virus) antibody preclinical experiment. Sorrento said that the STI-1499 antibody has COVID-19 virus infection on healthy cells. Has 100% inhibition. The company said last week that it plans to work with Mount Sinai Health System to develop antibody cocktail treatment for patients at risk or newly infected with COVID-19. According to reports, STI-1499 is also expected to be developed as a stand-alone therapy (COVI-GUARD™) because it has shown high efficacy in experiments so far. After the news was released, Sorrento Therapeutics stock price soared more than +158.02%.